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fits for human health. Those effects have been partially ascribed
to their content in flavonoids, compounds that are present in
many edible plants and its derived foods. In humans, a significant
number of studies has been developed analyzing the effect of
foods and beverages rich in flavonoids on the presence and pro 
gression of risk factors associated to cardiovascular diseases,
including hypertension. Cocoa derived products, rich in flavanols,
have been thoroughly studied and demonstrated to be efficient
improving endothelial function and decreasing blood pressure in
humans and animals. However, the final chemical species and the
mechanism/s responsible for these effects have not been com 
pletely defined. In this paper we present data supporting the
hypothesis that flavanols could define superoxide anion production
and then, establish optimal nitric oxide levels and blood pressure.
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Introduction Lifestyle modifications, including dietary habits, have sub-
stantial effects on risk factors for cardiovascular disease such
as hypertension.(1) Epidemiological evidence demonstrates that
diets rich in fruits and vegetables benefit heart and vascular
health.(2–11) Molecularly, these beneficial effects of fruits and
vegetables have been largely ascribed to their content in flavo-
noids. These compounds are synthesized in many edible plants
and remain present when plants are processed to foods. Grapes
and wine, cocoa and chocolate, black and green tea, and soy and
soy-derived products, are among the most important sources of
flavonoids in the human diet. A significant number of studies
has been developed in humans, analyzing the effect of foods and
beverages rich in flavonoids on the presence and progression of
risk factors associated to cardiovascular disease. Cocoa derived
products have been thoroughly studied and demonstrated to be
efficient improving endothelial function and decreasing blood
pressure (BP).(12–14)
BP is influenced and regulated by a variety of conditions and
chemical entities that interact among them in very complex ways.
These entities include from atoms, e.g., sodium, to well-orchestrated
systems, e.g., the renin-angiotensin system. In this complex
scheme, nitric oxide (NO) appears to play a pivotal role in the
regulation of vascular homeostasis, and then BP. We will focus
the discussion about the effects of dietary flavonoids, mainly those
provided by cocoa and cocoa products, on NO bioavailability as a
result of regulating steady-state levels of superoxide anion (O2￿−)
and oxidants in cells and tissues.
Nitric Oxide and Oxidants in Biological Systems
NO is produced from L-arginine in a reaction catalyzed by the
enzyme nitric oxide synthase (NOS). This enzyme is present in
mammals in different isoforms: endothelial (eNOS), neuronal
(nNOS), inducible (iNOS), which is expressed in response to
different stimulus, and mitochondrial (mtNOS). NO reacts with
several metal centers, molecular oxygen, thiol groups, and some
oxygen radicals. NO fulfills its most important physiological
action, i.e. vasodilation, by activating guanylyl cyclase through
the reaction with its heme group. The guanylyl cyclase catalyzes
the dephosphorylation of GTP to cGMP, which serves as a second
messenger for signaling smooth muscle relaxation. Alternatively,
NO reacts with superoxide anion, the one-electron reduction
product of oxygen in a near diffusion controlled reaction to form
peroxynitrite (NO + O2￿− → ONOO−). This reaction has two physio-
logical consequences: i) the generation of peroxynitrite which
can oxidize cell components;(15) and ii) the elimination of NO. In
this way, superoxide anion production is a modulator of NO
steady-state levels. In mammalian cells, the principal source of
superoxide anion is the mitochondrial electron transport, but
other enzymatic sources include NADPH oxidase (NOX), xanthine
oxidase, arachidonic acid metabolism by cyclooxygenase/lipoxy-
genase, and cytochrome P450.(16) In endothelial cells the NOX-
dependent superoxide production is particularly relevant.
Flavanols
Cocoa, and foods and beverages made with, contain important
amounts of flavan-3-ols or flavanols, a subfamily of flavonoids.
Flavonoids include a large number of compounds that share a
basic chemical structure and are classified in different subfamilies
depending on specific substitution patterns.(17) Flavan-3-ols or
flavanols are defined by the presence of a hydroxyl group at
position 3 (ring C) and constitute the most complex subfamily
of flavonoids, ranging from simple monomers to the oligomeric
and polymeric forms, called procyanidins.(17) Monomers could be
present in the aglycone form or esterified with gallic acid to form
the gallate derivatives. Studies on the composition of cocoa
products have shown that non-esterified monomers of flavanols
and procyanidins are the quantitatively most important type of
flavonoids. Those chemical species have been identified as (−)-
epicatechin (EC) (Fig. 1A), (+)-catechin (Cat), and mostly B-type
procyanidins, that are oligomers of EC.(18,19) Importantly, regard-
less the manufacturing process applied and the raw material used
to produce chocolate, the main flavanol present in chocolate is
EC.(19,20)
In terms of the metabolization of flavanols by humans and
animals, it has been demonstrated that the gastric environment
does not affect flavanols and procyanidins stability, and they
transit with minimal modification to the small intestine where can
be absorbed.(21) EC reached detectable values in human plasma
after dietary administration of chocolate or cocoa derived pro-
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ducts.(22–25) These results demonstrate that the EC present in the
raw material, i.e. cocoa beans, even after the alterations suffered
by manufacturing and metabolization processes, is present in
tissues after its ingestion.
Flavanols and Human Blood Pressure
Pioneer observations by McCullough et al.(26) indicated that the
Kuna Indians of Panama have a very low incidence of hyper-
tension and cardiovascular disease, but when members of this tribe
moved to Panama urban places, their BP increased. The migration
leads to cultural changes including an important decrease in cocoa
consumption, making cocoa the potential responsible for the
observed changes in BP. Epidemiologically, a sub-study of the
Zutphen population showed that cocoa (chocolate) consumption
was associated with a decrease in BP and cardiovascular mortality.(5)
Intervention trials with cocoa and cocoa products have included
different groups of subjects: normotensive (young, old, overweight,
hypercholesterolemic), pre-hypertensive, hypertensive stage 1,
and hypertensive with impaired glucose tolerance. Most of the
studies showed that cocoa consumption was associated with a
decrease in BP.(27)
Hooper et al.(13) reviewed the effectiveness of different flavo-
noid subclasses and flavonoid-rich food sources on cardiovascular
disease, and one of the risk factors measured was BP. Through the
analysis of 133 trials, their three significant conclusions were: i)
chocolate decreased diastolic BP and systolic BP (SBP); ii) soy
protein isolate (and no other soy derived products) decreased
diastolic BP; and iii) acute ingestion of black tea increased SBP
and diastolic BP. In the same direction, another meta-analysis
about the effects of cocoa and tea on BP, showed that foods rich in
cocoa may reduce, while tea intake appears to have no effect on
BP.(12) A new and recent meta-analysis evaluating the effect of
cocoa rich-foods on BP of hypertensive and normotensive
individuals concludes that dark chocolate is superior to placebo
in reducing systolic hypertension or diastolic prehypertension.(14)
In contrast to studies using chocolate or cocoa preparations, only
few studies have been developed on human subjects by using
purified flavanols. One study was carried out by dietary supple-
mentation with (+)-catechin in obese and near-obese Japanese
children.(28) Results, stratified by the median of the initial BP
values, showed that consumption of 75 mg (+)-catechin/d for
24 w was effective in reducing SBP in the above-median category.
The studies with isolated flavanols are crucial to assess these
Fig. 1. Dietary (−) epicatechin (EC) and blood pressure. A: chemical structure of EC; B: systolic blood pressure (SBP) of rats subjected to L NAME
pre treatment (40 mg/kg/d in drinking water) for 6 days; and C: SBP of rats administered with L NAME (open square), or L NAME + EC 0.4 g/100 g
diet (closed square) during the subsequent 8 days. Sprague–Dawley rats (130–140 g) were maintained under controlled housing conditions. SBP was
measured in preconditioned, conscious and restrained rats by tail cuff plethysmography. Data are presented as means ± SEM. Groups were
compared using ANOVA. *: p<0.05 respect to day zero of treatment (B), or to L NAME treated rats (C). J. Clin. Biochem. Nutr. | January | vol. 48 | no. 1 | 65
©2011 JCBN
C.G. Fraga et al.
compounds as responsible for the antihypertensive effects of
flavanol containing foods.
Flavanols, Nitric Oxide and Oxidative Stress in Human
Studies
The BP-lowering effect of cocoa-rich products have been
correlated with: i) increases in plasma or urine NO-derived
species; ii) improvement in NO-mediated flow-mediated dilation
(FMD) as an indicative of vascular function; and iii) reduced
oxidative stress. Plasma NO metabolites (measured as S-
nitrosothiols) were increased in prehypertensive and hypertensive
patients after 18 weeks consuming daily 6.3 g of chocolate (30 mg
of polyphenols).(29) The oral ingestion of a high-flavanol cocoa
drink (917 mg of flavonols) resulted in a transient increase in NO-
derived species concentration in plasma and urine of healthy
subjects.(30) This increase was associated with the improvement of
FMD, and with plasma flavanol levels. More recently, the oral
ingestion of 200 mg of quercetin or EC was also associated with
increased plasma and urine NO metabolites.(31) FMD was improved
in hypertensive individuals (with and without impaired glucose
tolerance) in association with decreased BP after 2 weeks con-
suming 100 g of chocolate.(32,33) Engler et al.(34) treated normoten-
sive individuals for 2 weeks with chocolate and did not find any
difference in BP and oxidative stress parameters, but a significant
increase in FMD. However, Fraga et al.(35) also working with a
normotensive group and chocolate supplementation for 2 weeks,
found positive results: decrease in BP associated to improvement in
oxidative stress markers (plasma malondialdehyde, vitamin E/low
density lipoprotein (LDL), vitamin E/cholesterol). More recently,
an intervention study administering cocoa beverage to a group of
subjects with essential hypertension for 2 weeks was developed.(36)
There were no changes in BP, but the insulin-mediated changes in
brachial diameter were higher in cocoa treated patients than in
placebo group. In another study, it was observed that two different
doses of polyphenols (500 mg or 1000 mg during 2 weeks) were
equally effective in reducing BP.(37)
One important factor to consider when an integrative conclu-
sion wants to be drawn from all these investigations is the
composition of the chocolate used. Unfortunately, there is not a
standardized chocolate or a consistent standardization (qualitative
and/or quantitative) of the chocolate components through the
different studies. Animal studies using purified compounds are
a valid alternative to advance on the comprehension of the
mechanisms underlying the BP lowering effect of cocoa derived
products.
Flavanols, Nitric Oxide and Oxidative Stress in Animal
Studies
Mechanistic aspects defining the beneficial effect of flavonoid-
rich diets on endothelial function and BP have been studied in a
variety of animal experimental models.(27,38) However, only a few
studies have been carried out by using cocoa derived products. A
commercially available natural flavonoid-enriched cocoa powder
was tested in spontaneously hypertensive rats (SHR). A single oral
administration of different doses of the product (50–600 mg/kg)
produced an antihypertensive effect in SHR without modifications
in the BP of normotensive Wistar-Kyoto rats. The maximum effect
on BP, caused by 300 mg/kg of powder, produced a BP decrease
similar to the one obtained with 50 mg/kg captopril (an angio-
tensin converting enzyme inhibitor).(39) More recently, the same
flavonoid-enriched cocoa powder was studied as antihypertensive
in SHR in a long-term treatment. Animals received the flavonoid-
enriched cocoa powder in the drinking water at doses 100, 200
and 400 mg/kg/d during 20 weeks. All the doses attenuated the
development of hypertension and improved the endothelial func-
tion in SHR.(40) However, the higher antihypertensive effect was
observed in the group treated with the lowest dose.(40)
A more mechanistic approach has been studied by using a
model of type 2 diabetes, the Otsuka Long-Evans Tokushima Fatty
(OLETF) rats, compared with nondiabetic Long-Evans Tokushima
Otsuka (LETO) rats. All rats were daily treated with (+)-catechin
(30 mg/kg/day) or saline for 12 weeks. OLETF rats showed an in-
crease in BP, associated with higher NOX activity and expression
of two NOX subunits (p22phox and p47phox) in aortic wall during
the studied period. Treatment of the OLETF rats with Cat resulted
in the maintenance of BP, arterial NOX activity and expression,
and the oxidative stress conditions in values similar to that ob-
served in saline-treated LETO rats.(41)
Being EC (Fig. 1A) the most abundant flavanol in cocoa, the
potential of this compound as responsible for the cocoa and
chocolate BP-lowering effect is of singular relevance. Sprague-
Dawley rats were pre-treated with the NO-synthase inhibitor Nω-
nitro-L-arginine methyl ester (L-NAME) in the drinking water
during 6 days. After that period, an increase of 25 mm Hg to 122 ±
6 mm Hg was observed (Fig. 1B). From that day, the rats were
maintained during 8 days under the same L-NAME treatment, but
receiving different diets: one group was fed with a control diet
(L-NAME group) and the second group with an EC-enriched diet
(0.4 g EC/100 g diet) (L-NAME + EC group). SBP was measured
during the following 8 days in both dietary groups. At the end of
that period, the group receiving control diet showed an additional
increase in BP. Meanwhile, the group receiving the diet supple-
mented with EC maintained the initial BP values (Fig. 1C). These
results suggest that the presence of EC in the diet can prevent the
sustained BP increase induced by a deficiency in NO production
associated to the L-NAME treatment.
The Hypothesis of Nitric Oxide Bioavailability
The concept of NO as a modulator of BP is centered in the fact
that sufficient NO bioavailability is associated with normal
vasodilation and normal BP. On the other hand, decreases in NO
steady-state concentration can lead to a failure in smooth muscle
relaxation and the consequent hypertension. As indicated, under
physiological conditions, most NO is produced by endothelial
cells due to eNOS activity. In response to inflammatory stimuli
NO can also be produced by iNOS in adventitia cells.(42) The small
size and lipophilic nature of NO allow the rapid diffusion of NO
through cell membranes to reach its target cells, the smooth
muscle cells.(15)
The principal sources of superoxide anion in the vasculature are
NOX activities, a family of oxidases that catalyze superoxide
anion production using NADPH as the electron donor. Three, out
of five NOX identified in animal tissues, have been reported in the
rat vasculature: NOX1 in smooth muscle cells; NOX2 in endo-
thelial and adventitial cells; and NOX4 in endothelial cells.(43)
Superoxide anion produced in the vascular wall will “consume”
the NO diffusing from the endothelial cells being determinant
of NO availability in the smooth muscle cells.
The processes involved in the maintenance of NO steady-state
level have multiple steps susceptible to be regulated by flavanols
(Fig. 2): i) decrease in superoxide anion and related oxidants
concentration in the cells by direct reaction (free radical scav-
enging action of EC);(44) ii) decrease in superoxide anion concen-
tration in the cell by diminishing NOX expression and/or activity;
iii) increase in NO production by augmentation of eNOS expres-
sion and/or activity; iv) modulation of enzymes and receptors
associated to ROS production, e.g., angiotensin II-mediated
pathways,(42,45) and v) protection of oxidative loss of tetrahydro-
biopterin to avoid eNOS uncoupling (a condition in which eNOS
produces large quantities of superoxide anion rather than NO).(46)
The final condition of optimal NO steady-state concentration can
be reached by either, increasing its synthesis (without modifica-
tion in its degradation), or by diminishing superoxide anion-doi: 10.3164/jcbn.11 010FR
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dependent NO loss. In the latter situation, an undesirable high
peroxynitrite formation is avoided and then, cells are protected
from oxidative and nitrosative damage.
The basic chemical features of EC, shared with most of the
flavonoids, allow them to act as classic antioxidants, i.e. free
radical scavengers and/or redox-active metal chelators. Even
though those antioxidant reactions are thermodynamically favored,
the actual concentration of flavonoids reached in the vasculature
makes quantitatively unfeasible these direct antioxidant mecha-
nisms.(47) Then, other biochemical mechanisms, probably related
to more specific interactions with proteins or lipids, should be
responsible for the in vivo effects of flavanols decreasing oxidative
stress. These mechanisms should be attained at the low flavanol
concentration observed (or estimated) to occur in most human and
animal tissues.
EC has been reported as responsible for eNOS activation in
human coronary artery endothelial cells culture.(48) EC treatment
activates eNOS via serine 633 and serine 1177 phosphorylation
and threonine 495 dephosphorylation, inducing eNOS dissociation
from the inhibitory protein caveolin-1. The authors propose that
EC effects are calcium-dependent and related to actions exerted at
the cell membrane level. In this line, we have postulated the lipid
rafts as targets for EC action.(49)
Other possible mechanism to increase NO production is to
preserve the intracellular arginine pool. Arginine, which is the
eNOS substrate, is also metabolized by the enzyme arginase.
Inhibition of arginase activity will limit NO production. Experi-
ments in human umbilical vein endothelial cells (HUVEC)
suggest the action of EC diminishing mRNA expression and
activity of arginase.(50) Moreover, dietary intervention with
flavanol-rich cocoa caused decreases in arginase activity in rat
kidney and human erythrocytes.(50)
In an interesting mechanistic study, EC was associated with
increased NO levels in HUVEC.(51) The authors observed a
decrease in superoxide anion concentration as a result of a direct
inhibition of NOX by EC metabolites. In addition, it was showed
that while EC is an efficient superoxide anion scavenger, its O-
methylated metabolites directly inhibit NOX. These metabolites
have been reported as predominant species after EC ingestion
by human and rats, and are structurally similar to apocynin, a
well-known NOX inhibitor.(51) Supporting this hypothesis, inhibi-
tion of the enzyme catechol-O-methyltransferase in HUVEC
preceding the EC treatments, prevented the NO increase. This
study indicates that methylation of EC could be essential to
inhibit NOX, and as a consequence, superoxide anion production.
Finally, changes in eNOS and/or NOX expression in aorta have
been reported in animals treated with purified compounds, such as
Cat,(41) the flavonol quercetin,(38) the polyphenol resveratrol(52) and
dietary extracts rich in flavonoids.(53,54) However, there is no data
about EC modifying the expression of those enzymes in the aortic
wall.
Conclusions
Flavanol containing foods, specially cocoa and cocoa-derived
products have demonstrated to have BP-lowering effects in both,
humans and animals. These effects could be related to the mainte-
nance of optimal NO levels, and could be associated with lowering
superoxide anion production in the vasculature.
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